What it is
Elamipretide (SS-31, MTP-131, Bendavia) is a synthetic water-soluble aromatic-cationic tetrapeptide with sequence D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2',6'-dimethyltyrosine), molecular weight 639.8 Da, CAS 736992-21-5, molecular formula C₃₂H₄₉N₉O₅. It was discovered by Hazel Szeto and Peter Schiller at Weill Cornell during structure–activity work on opioid analogs, where the alternating aromatic–cationic motif was found to drive selective inner-mitochondrial-membrane uptake independent of membrane potential. Unlike triphenylphosphonium-conjugated mito-targeted antioxidants, SS-31 partitions into the inner membrane by direct high-affinity binding to cardiolipin — the dimeric phospholipid unique to that membrane — making it the first-in-class cardiolipin-targeted therapeutic (Birk 2014, J Am Soc Nephrol; Mitchell 2020, PNAS). Stealth BioTherapeutics licensed the compound and developed it through Phase 3 trials in primary mitochondrial myopathy, heart failure, AMD, and Barth syndrome; only the Barth syndrome indication has reached FDA approval (accelerated, September 2025).
In plain English
Elamipretide (SS-31, Bendavia) is a synthetic four-amino-acid peptide designed to enter mitochondria — the energy factories inside cells — and stabilize a critical fat molecule called cardiolipin. Cardiolipin is found almost exclusively in the inner membrane of mitochondria and is essential for the machinery that generates ATP (the cell's main fuel). SS-31 concentrates inside mitochondria at levels 1,000–5,000 times higher than in the surrounding cell — and it does this even when the mitochondria are already damaged, which matters because most mito-targeted molecules need a healthy electrical charge gradient to get in. It was discovered at Weill Cornell Medical College by Hazel Szeto and Peter Schiller. Stealth BioTherapeutics took it through Phase 3 trials in four diseases. Only the Barth syndrome indication has reached FDA approval (accelerated, September 2025, brand name Forzinity).
How it works
- 01
Cardiolipin binding and inner-membrane targeting
Szeto (2014, Br J Pharmacol) and Birk (2014, J Am Soc Nephrol) established that SS-31 concentrates 1,000–5,000× in mitochondria of target tissues and binds cardiolipin with nanomolar affinity. Cardiolipin makes up 10–20 mol% of inner-mitochondrial-membrane lipid and is required for assembly of ETC supercomplexes and for cytochrome c tethering. Unlike conventional mito-targeted drugs, SS-31 uptake does not depend on membrane potential — which matters in dysfunctional mitochondria where ΔΨm is already depolarized.
In plain English
It concentrates inside mitochondria by sticking to a key fat molecule
Cardiolipin is a special fat molecule found almost exclusively in the inner membrane of mitochondria — where the cell's energy machinery lives. SS-31 binds cardiolipin with very high affinity and concentrates 1,000–5,000 times higher inside mitochondria than in the rest of the cell. Critically, it gets in even when the mitochondrial electrical charge is already low — which matters because damaged, dysfunctional mitochondria have often already lost that charge. Most mito-targeted drugs stop working when the mitochondria are already sick; SS-31 doesn't.
- 02
Electron transport chain supercomplex stabilization
Mitchell (2020, PNAS — the chemical cross-linking / mass spectrometry 'interaction landscape' paper cited in Stealth's Barth submission) identified the proteomic neighborhood of SS-31 at the inner membrane: ATP synthase subunits, Complex I/III/IV components, and the 2-oxoglutarate dehydrogenase complex — all cardiolipin-dependent. SS-31 improves coupling efficiency, preserves supercomplex formation, and restores ATP production in aged and diseased mitochondria without inhibiting normal respiration.
In plain English
It helps the cell's energy machinery work more efficiently
The energy machinery in mitochondria works best when its parts are organized into clusters called 'supercomplexes' — where multiple components pass electrons between each other efficiently. Cardiolipin is the structural glue that holds these clusters together. SS-31 protects cardiolipin and helps keep these energy-machine clusters intact. In aged and diseased mitochondria, it has been shown to restore ATP production without disrupting normal energy flow.
- 03
Reduction of mitochondrial ROS without blunting physiological redox signaling
The 2',6'-dimethyltyrosine residue scavenges hydroxyl and peroxynitrite radicals by forming stable tyrosyl radicals that couple to di-tyrosine — a mechanism that targets pathologic mitochondrial ROS without disrupting cytosolic redox tone. This is the pharmacological case for 'mitochondrial antioxidant' activity separate from broad antioxidant supplementation, which has failed repeatedly in clinical trials. Dai (2014, Aging Cell) showed reversal of age-related cardiac dysfunction in mice via this mechanism.
In plain English
It neutralizes harmful molecules inside mitochondria without disrupting normal cell chemistry
Damaged mitochondria produce excess harmful molecules called reactive oxygen species (ROS). One amino acid in SS-31's structure acts as a targeted scavenger of the most destructive types of ROS — the ones made inside mitochondria. The key distinction: it targets specifically harmful mitochondrial ROS without wiping out the lower-level signaling molecules the rest of the cell uses for normal function. This is the theoretical advantage over general antioxidant supplements (vitamin C, vitamin E, etc.), which have broadly failed in clinical trials.
- 04
Cytochrome c peroxidase inhibition and apoptosis-threshold raising
Cardiolipin-bound cytochrome c acquires peroxidase activity under oxidative stress; peroxidation of cardiolipin releases cytochrome c from the inner membrane and triggers intrinsic apoptosis. Birk (2014) showed SS-31 inhibits cyt-c peroxidase activity at sub-micromolar concentrations and prevents cardiolipin peroxidation, raising the threshold for apoptotic cascade activation in ischemia-reperfusion and in aged or tafazzin-deficient cells.
In plain English
It raises the point at which damaged cells start dying
Under oxidative stress, a protein called cytochrome c — normally anchored to cardiolipin in the inner membrane — can break free and trigger the cell's self-destruction program (apoptosis). SS-31 protects cardiolipin from being chemically damaged and keeps cytochrome c anchored in place, effectively raising the threshold at which cells start dying. This protective effect has been shown in heart-attack (ischemia-reperfusion) models and in cells from Barth syndrome patients.
- 05
Barth-specific rationale — tafazzin deficiency and cardiolipin remodeling
Barth syndrome is caused by loss-of-function mutations in TAZ (tafazzin), the transacylase that remodels immature monolysocardiolipin into mature tetralinoleoyl-cardiolipin. In tafazzin-deficient cells, SS-31 binds residual cardiolipin and restores supercomplex assembly even without normalizing the cardiolipin-species profile (Allen 2022, JAHA). This is the one indication where the drug-target biology is a close mechanistic fit, and it is the one indication where elamipretide has reached FDA approval.
In plain English
Why it especially fits Barth syndrome
Barth syndrome is caused by a mutation in a gene called TAZ (tafazzin), which is responsible for shaping cardiolipin into its mature form. Without functional tafazzin, cells build an abnormal cardiolipin and can't assemble their energy machinery properly. SS-31 binds whatever cardiolipin is available — even the abnormal kind — and helps reassemble the energy machinery around it. This is a close mechanistic match: a cardiolipin-binding drug for a cardiolipin-shaping disease. It is the only indication where the drug-target biology is a tight fit — and the only one where FDA approval was granted.
- 06
What is still unresolved
Why the preclinical-to-clinical translation has repeatedly failed outside Barth is not mechanistically explained. Candidate reasons include dosing regimen (40 mg SC daily may under-expose tissue compared to the continuous IV infusion protocols used in early trials), disease heterogeneity (PMM encompasses many distinct genotypes with differing cardiolipin dependence), trial duration (24–28 weeks may be too short for structural mitochondrial remodeling), and insufficient baseline mitochondrial dysfunction in the enrolled populations. None of these has been resolved by a follow-up positive trial.
In plain English
Why it keeps failing outside Barth — the main open questions
Three large controlled trials outside Barth syndrome have failed. Leading theories for why: (1) the daily under-skin injection may not deliver high enough doses to the tissue, since early positive preclinical work used continuous IV infusion; (2) diseases like primary mitochondrial myopathy are genetically too diverse — SS-31 may only help certain subtypes; (3) 24–28 weeks may not be long enough to see real mitochondrial structural repair; (4) the patients enrolled may not have had severe enough mitochondrial dysfunction to benefit. None of these explanations has been confirmed by a follow-up positive trial.